SG11201507430RA - Anti-egfr antibody drug conjugate formulations - Google Patents

Anti-egfr antibody drug conjugate formulations

Info

Publication number
SG11201507430RA
SG11201507430RA SG11201507430RA SG11201507430RA SG11201507430RA SG 11201507430R A SG11201507430R A SG 11201507430RA SG 11201507430R A SG11201507430R A SG 11201507430RA SG 11201507430R A SG11201507430R A SG 11201507430RA SG 11201507430R A SG11201507430R A SG 11201507430RA
Authority
SG
Singapore
Prior art keywords
drug conjugate
antibody drug
egfr antibody
conjugate formulations
formulations
Prior art date
Application number
SG11201507430RA
Inventor
Markus Tschoepe
Katharina Kaleta
Vineet Kumar
Original Assignee
Abbvie Deutschland
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland
Publication of SG11201507430RA publication Critical patent/SG11201507430RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
SG11201507430RA 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations SG11201507430RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790490P 2013-03-15 2013-03-15
PCT/US2014/027868 WO2014143765A1 (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations

Publications (1)

Publication Number Publication Date
SG11201507430RA true SG11201507430RA (en) 2015-10-29

Family

ID=50680154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707633VA SG10201707633VA (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations
SG11201507430RA SG11201507430RA (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201707633VA SG10201707633VA (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations

Country Status (28)

Country Link
US (2) US20140286969A1 (en)
EP (2) EP2968588B1 (en)
JP (4) JP6382935B2 (en)
KR (4) KR102305226B1 (en)
CN (2) CN105163763B (en)
AU (4) AU2014228172B2 (en)
BR (1) BR112015023391A8 (en)
CA (1) CA2906130A1 (en)
CY (1) CY1121949T1 (en)
DK (1) DK2968588T3 (en)
ES (1) ES2727134T3 (en)
HK (2) HK1217644A1 (en)
HR (1) HRP20190672T1 (en)
HU (1) HUE044071T2 (en)
IL (2) IL241009A0 (en)
LT (1) LT2968588T (en)
ME (1) ME03457B (en)
MX (2) MX2015012549A (en)
NZ (1) NZ630826A (en)
PL (1) PL2968588T3 (en)
PT (1) PT2968588T (en)
RS (1) RS58666B1 (en)
RU (2) RU2015144287A (en)
SG (2) SG10201707633VA (en)
SI (1) SI2968588T1 (en)
TR (1) TR201905313T4 (en)
TW (3) TW202146054A (en)
WO (1) WO2014143765A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2668209B8 (en) 2011-01-24 2021-08-11 Gilead Sciences, Inc. Antibodies selective for cells presenting egfr at high density
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AR099812A1 (en) 2014-03-21 2016-08-17 Abbvie Inc ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES
KR101628872B1 (en) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 Compounds comprising self-immolative group
CA2965362A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
US11413353B2 (en) 2015-11-25 2022-08-16 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CA3006247A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
WO2017201204A1 (en) * 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
AU2017277534A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
WO2018223958A1 (en) * 2017-06-06 2018-12-13 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
BR112020003474A2 (en) * 2017-08-23 2020-10-20 Daiichi Sankyo Company, Limited pharmaceutical composition, and method for producing a pharmaceutical composition
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
MX2020011554A (en) 2018-05-09 2020-11-24 Legochem Biosciences Inc Compositions and methods related to anti-cd19 antibody drug conjugates.
CN110960490A (en) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 anti-EGFR antibody coupling pharmaceutical composition and application thereof
MX2021009851A (en) 2019-02-18 2021-09-10 Lilly Co Eli Therapeutic antibody formulation.
WO2020192693A1 (en) * 2019-03-26 2020-10-01 荣昌生物制药(烟台)股份有限公司 Anti-her2 antibody drug conjugate pharmaceutical preparation
CN111939267A (en) * 2019-05-17 2020-11-17 百奥泰生物制药股份有限公司 Antibody-drug conjugate preparation, preparation method and application
KR20210028544A (en) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
CN112516090B (en) * 2019-09-18 2023-06-20 上海复旦张江生物医药股份有限公司 Pharmaceutical composition of antibody coupled drug, freeze drying agent, preparation method and application
AU2021243073A1 (en) * 2020-03-25 2022-10-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
JP2023521422A (en) * 2020-04-10 2023-05-24 ランタン ファルマ インコーポレイテッド Hydroxylureamethyl-acylfulvene for the treatment of brain cancer or CNS cancer
EP4245319A1 (en) * 2020-11-11 2023-09-20 The Catholic University of Korea Industry-Academic Cooperation Foundation Antibody-based conjugate for enhancing therapeutic effect of targeted therapeutic agent
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
CN115300623A (en) * 2021-05-08 2022-11-08 盛禾(中国)生物制药有限公司 Compositions of anti-EGFR fusion proteins or antigen binding fragments thereof and uses thereof
US20230027739A1 (en) 2021-05-10 2023-01-26 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN114740108B (en) * 2022-03-28 2023-07-14 天津键凯科技有限公司 Method for measuring modification degree of polymer modified antibody drug
WO2023240223A2 (en) * 2022-06-10 2023-12-14 Acelyrin, Inc. Anti-igf-1r antibody compositions
WO2023241663A1 (en) * 2022-06-15 2023-12-21 上海翰森生物医药科技有限公司 Pharmaceutical composition comprising antibody-drug conjugate and use thereof
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (en) 1988-09-02 2006-04-26 ダイアックス コープ． Generation and selection of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
ES2166368T3 (en) * 1993-12-24 2002-04-16 Merck Patent Gmbh IMMUNOCONJUGADOS.
PT1231268E (en) 1994-01-31 2005-11-30 Univ Boston BANKS OF POLYCLONE ANTIBODIES
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004074163A1 (en) * 2003-02-14 2004-09-02 Rubbermaid Commercial Products Llc Liquid dispenser
BR122018071968B8 (en) 2003-11-06 2021-07-27 Seattle Genetics Inc antibody-drug conjugate, pharmaceutical composition, article of manufacture and use of an antibody-drug conjugate
JP4942643B2 (en) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド Partially added antibodies and methods for conjugating them
US7662936B2 (en) * 2004-04-07 2010-02-16 Genentech, Inc. Mass spectrometry of antibody conjugates
NZ580115A (en) * 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
EP4026840A1 (en) 2005-07-18 2022-07-13 Seagen Inc. Beta-glucuronide-linker drug conjugates
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
IN2012DN02737A (en) * 2009-09-01 2015-09-11 Abbott Lab
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AU2011227335B2 (en) * 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
CA2798273A1 (en) * 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
UA116189C2 (en) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. FORMULATION FOR ANTI-α4β7 ANTIBODY
AU2014240012A1 (en) * 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
NZ723399A (en) * 2014-02-18 2020-08-28 Illumina Inc Methods and compositions for dna profiling

Also Published As

Publication number Publication date
US20200282072A1 (en) 2020-09-10
HK1217644A1 (en) 2017-01-20
ME03457B (en) 2020-01-20
AU2014228172B2 (en) 2018-12-06
CA2906130A1 (en) 2014-09-18
JP6382935B2 (en) 2018-08-29
TW201945032A (en) 2019-12-01
BR112015023391A2 (en) 2017-11-28
CN105163763B (en) 2019-07-02
AU2023200432A1 (en) 2023-03-02
NZ630826A (en) 2017-06-30
HUE044071T2 (en) 2019-09-30
ES2727134T3 (en) 2019-10-14
CN105163763A (en) 2015-12-16
HRP20190672T1 (en) 2019-08-23
NZ732015A (en) 2022-01-28
KR102305226B1 (en) 2021-09-29
LT2968588T (en) 2019-05-10
KR20150131366A (en) 2015-11-24
JP2022126754A (en) 2022-08-30
AU2018267662A1 (en) 2018-12-13
CY1121949T1 (en) 2020-10-14
JP2018184468A (en) 2018-11-22
TWI689313B (en) 2020-04-01
TW201519903A (en) 2015-06-01
TR201905313T4 (en) 2019-05-21
BR112015023391A8 (en) 2018-01-30
RS58666B1 (en) 2019-06-28
EP2968588A1 (en) 2016-01-20
TW202146054A (en) 2021-12-16
SG10201707633VA (en) 2017-11-29
KR20220041957A (en) 2022-04-01
WO2014143765A1 (en) 2014-09-18
KR20220139443A (en) 2022-10-14
CN110433139A (en) 2019-11-12
WO2014143765A8 (en) 2015-09-11
JP2020143152A (en) 2020-09-10
AU2020277164A1 (en) 2020-12-24
MX2020000333A (en) 2020-07-13
KR20210118238A (en) 2021-09-29
RU2015144287A (en) 2017-04-24
HK1219044A1 (en) 2017-03-24
IL241009A0 (en) 2015-11-30
RU2015144287A3 (en) 2018-03-19
JP2016515511A (en) 2016-05-30
AU2014228172A1 (en) 2015-09-24
MX2015012549A (en) 2016-06-21
US20140286969A1 (en) 2014-09-25
RU2020125266A (en) 2020-09-24
PL2968588T3 (en) 2019-08-30
EP2968588B1 (en) 2019-01-09
PT2968588T (en) 2019-05-08
SI2968588T1 (en) 2019-05-31
IL274881A (en) 2020-07-30
DK2968588T3 (en) 2019-04-23
EP3517132A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
IL274881A (en) Anti-egfr antibody drug conjugate formulations
HK1210477A1 (en) Antibody drug conjugate
IL241277A0 (en) Antibody drug conjugates
IL291073A (en) Anti-egfr antibody drug conjugates
EP2982681B8 (en) Wt1-antigen peptide conjugate vaccine
ZA201508487B (en) Antibody drug conjugates
EP2968600A4 (en) Antibody drug conjugates
IL252441A0 (en) C-met antibody drug conjugate
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
ZA201600027B (en) Pharmaceutical preparation
ZA201506465B (en) Pharmaceutical preparation